checkAd

     134  0 Kommentare Numerous Presentations to Showcase Long-Term Efficacy & Safety of Glaukos Technologies at 2020 American Glaucoma Society Meeting

    Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retina diseases, announced today that its products will be featured in various presentations at the American Glaucoma Society (AGS) Annual Meeting beginning February 27, 2020 at the Gaylord National Resort & Convention Center in Washington D.C.

    Glaukos is hosting an educational symposium for surgeons during AGS entitled “Hot Topics in MIGS: The Evolving Transformation” on February 27 at 12:30 PM – 1:30 PM in the Eastern Shore Room 2 on the first floor of the convention center. The faculty includes Sahar Bedrood, MD; Alex Huang, MD; Paul Singh, MD; and Tom Samuelson, MD, who will moderate the symposium. Go here to register.

    Glaukos will be exhibiting on the showroom floor throughout AGS at booth B-5.

    Key surgeon poster presentations available for viewing during AGS in the Cherry Blossom Lobby include:

    Thursday, February 27

    7:00 AM – 8:00 AM Poster Presentation Session
    7:00 AM – 5:00 PM Poster Viewing

    • PO002 Sustained Five-Year Safety and Intraocular Pressure (IOP) Outcomes in Open-Angle Glaucoma (OAG) Subjects Treated with Trabecular Micro-Bypass Stents (iStent inject)
      Author: Jason Bacharach
    • PO014 Five-Year Outcomes of Two Second-Generation Trabecular Micro-Bypass Stents (iStent inject) Combined with Travoprost in OAG on Two Preoperative Medications
      Authors: Albert Khouri, Lilit Voskanyan, L. Jay Katz
    • PO015 The Efficacy of Two Trabecular Micro-Bypass Stents with Phacoemulsification Surgery Compared to Trabeculectomy with Phacoemulsification Surgery
      Authors: Michael Lawson, Sean Sykes, Lucy Ma, Jane Whitney, Sorana Raiciulescu, Won Kim, Jonathan Buttram
    • PO016 Long-Term Outcomes of iStent Trabecular Micro-Bypass Stenting with Cataract Surgery Including Visual Field (VF), Optical Coherence Tomography (OCT) and Disease Progression – Real-World Case Series
      Author: Richard Lehrer
    • PO030 Outcomes of the iStent Trabecular Micro-Bypass Implant: Three-Year Follow-Up
      Authors: Saba Samet, Jeb Ong, Devesh Varma, Iqbal Ike Ahmed
    • PO031 Real-World Experience with Second-Generation Trabecular Micro-Bypass Stents (iStent inject) Implanted in Conjunction with Phacoemulsification
      Author: Steven Sarkisian
    • PO037 Early Results of Second-Generation Trabecular Micro-Bypass Stents (iStent inject) with Cataract Surgery in a Real-World Setting
    Seite 1 von 5


    Business Wire (engl.)
    0 Follower
    Autor folgen

    Numerous Presentations to Showcase Long-Term Efficacy & Safety of Glaukos Technologies at 2020 American Glaucoma Society Meeting Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retina diseases, announced today that its products will be featured in …